– USA, CA – Asher Biotherapeutics, Inc., a biotechnology company developing precisely-targeted immunotherapies for cancer, chronic viral infections, and autoimmune disorders, today announced the appointment of Dr. Bob Deresiewicz (M.D.) to its Board as an Independent Director.
“Bob is an outstanding addition to our Board of Directors. As a highly regarded physician-scientist and savvy investor, he brings a unique understanding of how to build a successful biotechnology company, both in identifying and advancing quality science and developing a robust and resilient corporate strategy. ob’s inherent curiosity and commitment to rigorous research are well-aligned with our corporate culture and we look forward to his many contributions as we continue maturing Asher Bio and advancing our precision immunotherapies to the clinic,” said CEO, Dr. Craig Gibbs.
About Dr. Bob Deresiewicz
Dr. Deresiewicz is a recently retired partner, portfolio manager, and global industry analyst with Wellington Management Company, LLP.
Dr. Deresiewicz started at Wellington Management Company, LLP (Wellington), in 2000, where he served as a member of the firm’s healthcare investment team, specializing in biotechnology. Throughout his career, he managed or co-managed a variety of dedicated healthcare investment vehicles, including both public and private equity products. Before Wellington, Dr. Deresiewicz was an assistant professor of medicine at Harvard Medical School and an associate physician in the Division of Infectious Diseases at Brigham and Women’s Hospital. He trained in infectious disease at Harvard Medical School, in tropical medicine at Hadassah Medical School in Jerusalem, and in internal medicine at Columbia-Presbyterian Medical Center in New York.
“As an early investor in Asher Bio, I have had the opportunity to follow the company closely and have been consistently impressed by the team’s scientific approach and execution,” said Dr. Deresiewicz. “I believe Asher Bio’s cis-targeted cytokines have the potential to solve the long-standing challenge of safely harnessing potent immunomodulators for therapeutic use by precisely delivering them to the desired effector cells while avoiding cell types associated with toxicity. I look forward to working with the management team and Board to advance these programs and ultimately to delivering important new medicines that meaningfully improve the standard of care for people living with cancer, autoimmune disease, or another infectious disease.”
Dr. Deresiewicz holds an M.B.A. from Harvard Business School, an M.D. from Mount Sinai School of Medicine, and a B.A. in Biochemistry from Columbia University. He was Board Certified in Internal Medicine and Infectious Diseases and was an elected fellow of the American College of Physicians and the Infectious Disease Society of America.
About Asher Bio
Asher Bio is a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infections, and autoimmune disorders. We utilize our proprietary cis-targeting platform to develop therapies engineered to overcome the limitations of other immune-based treatments by selectively activating specific immune cell types with validated disease-fighting functionality. Our candidates feature an antibody connected to a modified immunomodulatory protein, such as a cytokine. Our candidate design is intended to enable our candidates to selectively activate the desired immune cells and not other cells that contribute to toxicity or immune suppression. Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco.
For more information: https://asherbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.